Verena Wally1, Alain Hovnanian2, Juliette Ly2, Hana Buckova3, Victoria Brunner4, Thomas Lettner4, Michael Ablinger4, Thomas K Felder5, Peter Hofbauer6, Martin Wolkersdorfer6, Florian B Lagler7, Wolfgang Hitzl8, Martin Laimer9, Sophie Kitzmüller4, Anja Diem4, Johann W Bauer9. 1. EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. Electronic address: v.wally@salk.at. 2. INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France; University Paris Descartes-Sorbonne Paris Cité, Paris, France; Department of Genetics, Necker Hospital, AP-HP, Paris, France. 3. Department of Pediatric Dermatology, Children's Hospital, Brno, Czech Republic. 4. EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. 5. Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria. 6. Landesapotheke Salzburg, Department of Production, Hospital Pharmacy, Salzburg, Austria. 7. Institute for Inborn Errors of Metabolism, Paracelsus Medical University, Salzburg, Austria; Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria. 8. Research Office Biostatistics, Paracelsus Medical University, Salzburg, Austria. 9. Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Abstract
BACKGROUND: Epidermolysis bullosa simplex (EBS) is a rare genetic, blistering skin disease for which there is no cure. Treatments that address the pathophysiology of EBS are needed. OBJECTIVE: Compare the impact of 1% diacerein cream with placebo in reducing the number of blisters in EBS. METHODS: In a randomized, placebo-controlled, phase 2/3 trial we used a 1% diacerein topical formulation to treat defined skin areas in 17 patients. In a 2-period crossover trial, patients were randomized to either placebo or diacerein for a 4-week treatment and a 3-month follow-up in period 1. After a washout, patients were crossed over during period 2. The prespecified primary end point was the proportion of patients with a reduction of number of blisters by more than 40% from baseline in selected areas over the treatment episode. RESULTS: Of the patients receiving diacerein, 86% in episode 1 and 37.5% in episode 2 met the primary end point (vs 14% and 17% with placebo, respectively). This effect was still significant after the follow-up. Changes in absolute blister numbers were significant for the diacerein group only. No adverse effects were observed. LIMITATIONS: Low patient numbers and no invasive data acquisition because of clinical burden in children. CONCLUSION: This trial provides evidence of the impact of 1% diacerein cream in the treatment of EBS.
BACKGROUND: Epidermolysis bullosa simplex (EBS) is a rare genetic, blistering skin disease for which there is no cure. Treatments that address the pathophysiology of EBS are needed. OBJECTIVE: Compare the impact of 1% diacerein cream with placebo in reducing the number of blisters in EBS. METHODS: In a randomized, placebo-controlled, phase 2/3 trial we used a 1% diacerein topical formulation to treat defined skin areas in 17 patients. In a 2-period crossover trial, patients were randomized to either placebo or diacerein for a 4-week treatment and a 3-month follow-up in period 1. After a washout, patients were crossed over during period 2. The prespecified primary end point was the proportion of patients with a reduction of number of blisters by more than 40% from baseline in selected areas over the treatment episode. RESULTS: Of the patients receiving diacerein, 86% in episode 1 and 37.5% in episode 2 met the primary end point (vs 14% and 17% with placebo, respectively). This effect was still significant after the follow-up. Changes in absolute blister numbers were significant for the diacerein group only. No adverse effects were observed. LIMITATIONS: Low patient numbers and no invasive data acquisition because of clinical burden in children. CONCLUSION: This trial provides evidence of the impact of 1% diacerein cream in the treatment of EBS.
Authors: James A Feinstein; Purevsuren Jambal; Kathleen Peoples; Anne W Lucky; Phuong Khuu; Jean Y Tang; Irene Lara-Corrales; Elena Pope; Karen Wiss; Kristen P Hook; Laura E Levin; Kimberly D Morel; Amy S Paller; Catherine C McCuaig; Julie Powell; Lawrence F Eichenfield; Harper Price; Moise L Levy; Lawrence A Schachner; John C Browning; Susan Bayliss; Marla Jahnke; Tor Shwayder; Sharon A Glick; Anna L Bruckner Journal: JAMA Dermatol Date: 2019-02-01 Impact factor: 10.282
Authors: P Peking; J S Breitenbach; M Ablinger; W H Muss; F J Poetschke; T Kocher; U Koller; S Hainzl; S Kitzmueller; J W Bauer; J Reichelt; T Lettner; V Wally Journal: Br J Dermatol Date: 2018-10-07 Impact factor: 9.302
Authors: Dedee F Murrell; Amy S Paller; Christine Bodemer; John Browning; Milos Nikolic; Jay A Barth; Hjalmar Lagast; Eva Krusinska; Allen Reha Journal: Orphanet J Rare Dis Date: 2020-07-21 Impact factor: 4.123
Authors: Michael Ablinger; Thomas K Felder; Monika Wimmer; Roland Zauner; Peter Hofbauer; Thomas Lettner; Martin Wolkersdorfer; Florian B Lagler; Anja Diem; Johann W Bauer; Verena Wally Journal: Orphanet J Rare Dis Date: 2018-11-01 Impact factor: 4.123